Academic Journal
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
| Title: | BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting |
|---|---|
| Authors: | Huijian Zheng, Huajian Xian, Wenjie Zhang, Chaoqun Lu, Renyao Pan, Han Liu, Zhenshu Xu |
| Source: | Journal of Hematology & Oncology, Vol 18, Iss 1, Pp 1-4 (2025) |
| Publisher Information: | BMC, 2025. |
| Publication Year: | 2025 |
| Collection: | LCC:Diseases of the blood and blood-forming organs LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | BCMA-targeted therapies, Multiple myeloma, ASH 2024, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Abstract B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1756-8722 |
| Relation: | https://doaj.org/toc/1756-8722 |
| DOI: | 10.1186/s13045-025-01675-5 |
| Access URL: | https://doaj.org/article/037e45ce3b4142e0884e39c2707cfda0 |
| Accession Number: | edsdoj.037e45ce3b4142e0884e39c2707cfda0 |
| Database: | Directory of Open Access Journals |
| Full text is not displayed to guests. | Login for full access. |
| ISSN: | 17568722 |
|---|---|
| DOI: | 10.1186/s13045-025-01675-5 |
| Published in: | Journal of Hematology & Oncology |
| Language: | English |